Clinical Trials
13
Active:0
Completed:7
Trial Phases
3 Phases
Phase 1:6
Phase 2:6
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (46.2%)Phase 2
6 (46.2%)Phase 3
1 (7.7%)An Bioequivalence Study of Loxoprofen Sodium Patches in Healthy Volunteers
Phase 1
Not yet recruiting
- Conditions
- OsteoarthritisMuscle PainSwelling Muscle
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Frontier Biotechnologies Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06510413
Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- Frontier Biotechnologies Inc.
- Target Recruit Count
- 1336
- Registration Number
- NCT05675072
- Locations
- 🇨🇳
Shenzhen Third People's Hospital, Shenzhen, Guangdong, China
A Study of FB2001 for Inhalation in Healthy Chinese Adults
Phase 1
Completed
- Conditions
- COVID-19 Pandemic
- Interventions
- Drug: FB2001 for inhalationDrug: FB2001 for inhalation placebo
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- Frontier Biotechnologies Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05583812
- Locations
- 🇨🇳
The Third Hospital of Changsha, Changsha, China
Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- Frontier Biotechnologies Inc.
- Target Recruit Count
- 1188
- Registration Number
- NCT05445934
- Locations
- 🇨🇳
Huashan Hospital Fudan University, Shanghai, Shanghai, China
🇨🇳Beijing Ditan Hospital Capital Medical University, Beijing, China
Study to Evaluate Pharmacokinetic and Safety of Albuvirtide Between Intravenous Drip and Intravenous Injection
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- Frontier Biotechnologies Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05206019
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, China
- Prev
- 1
- 2
- 3
- Next
News
No news found